Lobe Sciences Ltd.

LOBE

CA53946V2066

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 10:42:35 2024-04-26 am EDT			5-day change	1st Jan Change
0.02 ^CAD	0.00%		+33.33%	-20.00%

Feb. 15	Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	CI
2023	Lobe Sciences Provides Update on L-130 Clinical Program	MT

Lobe Sciences Ltd. Announces Resignation of Jonathan Gilbert of Board Chairman

October 03, 2022 at 05:47 pm EDT

Lobe Sciences Ltd. announced that on October 3, 2022, Jonathan Gilbert and the Company entered into a mutual separation agreement whereby Mr. Gilbert agreed to resign as Executive Chairman of the board of directors of the Company, effective immediately.

Latest news about Lobe Sciences Ltd.

Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	Feb. 15	CI
Lobe Sciences Provides Update on L-130 Clinical Program	Dec. 07	MT
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program	Dec. 07	CI
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	Dec. 05	MT
Lobe Sciences Appoints CFO	23-09-18	MT
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer	23-09-18	CI
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement	23-09-15	MT
Lobe Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-08-01	CI
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130	23-06-27	CI
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer	23-06-07	CI
Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-28	CI
Lobe Sciences Ltd. completed the acquisition of Altemia and Company, LLC from Sancilio, LLC, PBHC1, LLC and Bruce Crawford for CAD 3.8 million.	23-04-17	CI
Lobe Sciences Ltd. signed a share purchase agreement to acquire Altemia and Company, LLC for CAD 3.8 million.	23-04-17	CI
Lobe Sciences Ltd. announced that it expects to receive $0.25 million in funding	23-02-09	CI
Lobe Sciences Ltd. Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-30	CI
Lobe Sciences Ltd. Auditor Raises 'Going Concern' Doubt	22-12-21	CI
Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2022	22-12-21	CI
Lobe Sciences Ltd. Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130	22-11-30	CI
Lobe Sciences Ltd. Appoints Baxter F. Phillips III to the Board of Directors	22-10-05	CI
Lobe Sciences Ltd. Announces Resignation of Jonathan Gilbert of Board Chairman	22-10-03	CI
Lobe Sciences Ltd. Announces the Expansion of Its Patent Portfolio with International Filings	22-10-03	CI
Lobe Sciences Ltd. announced that it has received CAD 1.41314 million in funding	22-09-07	CI
Lobe Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022	22-07-20	CI
Lobe Sciences Ltd. and Clearway Global Llc Enters into A Development Agreement	22-06-21	CI
YourWay Cannabis Brands Inc. entered into a definitive arrangement agreement to acquire Ionic Brands Corp. from Lobe Sciences Ltd., Ionic Brands' officers, directors and other shareholders for CAD 2.2 million.	22-04-19	CI

Chart Lobe Sciences Ltd.

Duration

Period

More charts

Company Profile

Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
LOBE SCIENCES LTD.	-20.00%	2.41M
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B

Alternative Medicine